Consequently, radiotherapy-based LCT might play pivotal roles, such as enhancing systemic anti-tumor immune responses and fostering long-term survival, in patients treated with PD-1/PD-L1 inhibitors for metastatic NSCLC with ORD, meriting further examination. This evidence concerns the gene CD274 and neoplasm.